Impact Factor
3.34
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
2.97
487 total citations
h5-index
27
h5 depth signal
Cited share
66.8%
127 of 190
Total citations
487
Citation footprint
Metric signal
2.76
External metric anchor
Self-citation
3.1%
15 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
United States
640
United Kingdom
180
Canada
80
Australia
57
Netherlands
30
Citing Fields of Research
Medical Ethics
489
Statistical Methods
400
Oncology
77
Health Education & Remote Healthcare
76
Patient Care
70
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
1,937
Articles tracked across the journal lifetime
Indexed publication set
190
127 cited publications
Last 12 months
75
6.3 publications/month
Open access share
50.7%
38 OA publications in the last year
Leading citing country
United States
640 citing publications
Leading citing field
Medical Ethics
489 citing publications
Latest tracked publication
16 October 2026
10 recent records available
Coverage & Indexing History
v1n1, Feb. 2004-
v1n1, Feb. 2004-
Active Coverage
Research Focus & Classification
Indexed Subjects
Statistical Methods
Medical Ethics
Issuing & Sponsoring Bodies
Contributor
Society for Clinical Trials (U.S.)
Broad Categories
Medicine
Therapeutics
Medical Ethics
Statistical Methods
MeSH Descriptors
Clinical Trials as Topic
Research Design
Therapies, Investigational
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.1177/17407745261491903
Open DOI
Automated surveillance of primary outcome reporting in clinical trials: Development and validation of a scalable screening pipeline
Background: Detecting discrepancies between registered and published trial outcomes currently requires manual expert review, limiting surveillance to small samples. No scalable automated system exists for continuous monitoring of outcome...
02
DOI 10.1177/17407745261488366
Open DOI
Audit and feedback interventions for recruitment and retention in clinical trials: A systematic review
Background/aims: This study had two objectives: (1) to determine the effectiveness of audit and feedback interventions for improving recruitment and retention in randomised controlled trials (hereinafter referred to as trials) and (2) to...
03
DOI 10.1177/17407745261488336
Open DOI
Implementation challenges in a community-based randomized clinical trial in the rural settings of India
Background: Community-based randomized controlled trials are the benchmark for evaluating public health interventions due to their real-world relevance. However, their implementation, particularly in resource-limited, rural settings, is ...
04
DOI 10.1177/17407745261491900
Open DOI
Transparency of clinical trials: Reproducing and extending analyses
Background: Between 2021 and 2023, deidentified patient-level data and associated programming code from the biologics license application for Pfizer’s covid-19 vaccine were published on the Internet. The release, which appears to be unpr...
05
DOI 10.1177/17407745261474080
Open DOI
Are safety lead-in phase II clinical trials really safe?
Background/Aims: Phase II trials with a safety lead-in (SLI), allowing one or two dose de-escalations based on toxicities from the first several patients at a dose, are increasingly common in oncology. Despite increased demand, formal ev...
06
DOI 10.1177/17407745261471455
Open DOI
New oncology trial designs and equipoise: Commentary on Heynemann et al.
This essay responds to Heymemann et al.’s analysis of the applicability of clinical equipoise to emerging trial methods in cancer. Briefly, I argue that equipoise presses study designers to conduct trials at the point of maximum communit...
07
DOI 10.1177/17407745261469887
Open DOI
Uncertainty and novel clinical trial designs in oncology – when should equipoise matter?
Equipoise is usually considered a requirement for the ethical conduct of phase III randomised controlled trials. Notwithstanding theoretical critiques since the concept’s initial proposal, equipoise has remained an important moral consid...
08
DOI 10.1177/17407745261474443
Open DOI
A classification of incomplete stepped wedge cluster randomised trial designs
Background/aims: Stepped wedge designs are cluster randomised trial designs for testing new interventions through a phased rollout of the intervention across clusters. In many trial settings, a complete stepped wedge design can place a s...
09
DOI 10.1177/17407745261471462
Open DOI
How to be SMART in oncology: A practical framework to assess the contribution of phase using sequential multiple adaptive randomized treatment designs
Background: Sequential multiple adaptive randomized treatment designs can generate registrational-quality evidence for the contribution of phase in perioperative oncology by preserving randomized comparisons and intent-to-treat estimatio...
10
DOI 10.1177/17407745261467982
Open DOI
A practical application for the efficient use of historical data in randomized controlled design using systematic review data
Introduction: Randomized controlled trials are the gold standard for evaluating interventions but are resource-intensive and impose considerable burden on participants. Historical control designs, which incorporate data from previous tri...
Bibliographical & Catalog Notes
Title from cover.
Also issued online.
v. 1, no. 1 (Feb. 2004)20050727 Notice published Printed on acid-free paper